Wells Fargo & Company MN Bought 29,701 Shares of Five Prime Therapeutics Inc (FPRX)

Wells Fargo & Company MN Bought 29,701 Shares of Five Prime Therapeutics Inc (FPRX)

Wells Fargo & Company MN increased its stake in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 19.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 185,266 shares of the biotechnology company’s stock after buying an additional 29,701 shares during the period. Wells Fargo & Company MN’s holdings in Five Prime Therapeutics were worth $6,697,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of FPRX. Dimensional Fund Advisors LP boosted its stake in Five Prime Therapeutics by 12.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 841,072 shares of the biotechnology company’s stock valued at $42,147,000 after buying an additional 93,211 shares during the last quarter. Teachers Advisors LLC boosted its stake in Five Prime Therapeutics by 0.7% in the fourth quarter. Teachers Advisors LLC now owns 238,428 shares of the biotechnology company’s stock valued at $11,948,000 after buying an additional 1,558 shares during the last quarter. Advisory Research Inc. bought a new stake in Five Prime Therapeutics during the fourth quarter valued at $1,367,000. Creative Planning boosted its stake in Five Prime Therapeutics by 42.6% in the first quarter. Creative Planning now owns 6,690 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 2,000 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new stake in Five Prime Therapeutics during the fourth quarter valued at $8,181,000. Hedge funds and other institutional investors own 93.38% of the company’s stock.

Five Prime Therapeutics Inc (NASDAQ:FPRX) opened at 29.70 on Tuesday. The stock has a 50 day moving average of $31.03 and a 200 day moving average of $42.23. Five Prime Therapeutics Inc has a 52 week low of $27.01 and a 52 week high of $60.98. The company’s market cap is $828.54 million.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($1.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.25. Five Prime Therapeutics had a net margin of 64.94% and a return on equity of 59.23%. The firm had revenue of $10.13 million during the quarter, compared to analyst estimates of $6.05 million. During the same period in the prior year, the company earned ($0.49) EPS. The business’s quarterly revenue was up 55.8% compared to the same quarter last year. Equities research analysts predict that Five Prime Therapeutics Inc will post ($4.60) earnings per share for the current fiscal year.

Several equities research analysts have weighed in on FPRX shares. Nomura started coverage on shares of Five Prime Therapeutics in a research report on Wednesday, March 1st. They issued a “buy” rating for the company. Cowen and Company started coverage on shares of Five Prime Therapeutics in a research report on Friday, March 24th. They issued an “outperform” rating for the company. Instinet started coverage on shares of Five Prime Therapeutics in a research report on Wednesday, March 1st. They issued a “buy” rating and a $94.00 price objective for the company. TheStreet cut shares of Five Prime Therapeutics from a “c” rating to a “d+” rating in a research report on Monday, March 20th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $55.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, May 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Five Prime Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $60.83.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:FPRX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).

Related posts

Leave a Comment